Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 5/20 | 0.60 |
| ▸ | FAAH | O00519 | 5/20 | 0.54 |
| ▸ | ACHE | P22303 | 5/20 | 0.54 |
| ▸ | BCHE | P06276 | 3/20 | 0.54 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | ACACB | O00763 | 1/20 | 0.46 |
| ▸ | CKS1B | P61024 | 1/20 | 0.45 |
| ▸ | SKP1 | P63208 | 1/20 | 0.45 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23920648 | 0.87 | ATF4 (0.64) | ATF4DRD2ACACB | |
| SCHEMBL21882045 | 0.85 | ATF4 (0.76) | ATF4ALDH1A1 | |
| SCHEMBL22777707 | 0.85 | ATF4 (0.67) | ATF4FAAHACHEBCHEALDH1A1 | |
| SCHEMBL23920510 | 0.83 | ATF4 (0.66) | ATF4FAAHACHEBCHEACACB | |
| SCHEMBL28724351 | 0.83 | ATF4 (0.66) | ATF4FAAHACHEBCHEACACB | |
| SCHEMBL19709173 | 0.82 | SMN1; SMN2 (0.54) | ATF4FAAHACHEBCHEDRD2 | |
| SCHEMBL22777617 | 0.81 | ATF4 (0.62) | ATF4FAAHACHEBCHEALDH1A1 | |
| SCHEMBL23920295 | 0.79 | ATF4 (0.72) | ATF4FAAHACHEBCHEALDH1A1 | |
| SCHEMBL21004138 | 0.78 | SIGMAR1 (0.49) | FAAHACHEBCHEDRD2ALDH1A1 | |
| SCHEMBL29525453 | 0.77 | CCR2 (0.55) | FAAHACHEBCHEDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3983378-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | Praxis Biotech LLC (US) | 2022-04-20 | — | — | EP | disclosed |
| CN-114206829-A | Integrated stress response pathway inhibitors | 普拉西斯生物技术有限责任公司 | 2022-03-18 | — | — | CN | disclosed |
| US-20210317102-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | ALTOS LABS, INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317102-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | ATF4, DDIT3, ATF1 | ATF4 1/4885FAAH 2722/4885ACHE 4843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.